"CD40 Antigens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Members of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. They are found on mature B-LYMPHOCYTES, some EPITHELIAL CELLS; and lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations in the CD40 antigen gene result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D019013
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.097 D23.050.301.264.051.140 D23.101.100.150.140
|
| Concept/Terms |
CD40 Antigens- CD40 Antigens
- TNFRSF5 Receptor
- Receptor, TNFRSF5
- CDw40 Antigen
- Antigen, CDw40
- Tumor Necrosis Factor Receptor Superfamily, Member 5
- CD40 Antigen
- Antigen, CD40
- Antigens, CD40
|
Below are MeSH descriptors whose meaning is more general than "CD40 Antigens".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]
- CD40 Antigens [D12.776.543.750.705.852.760.097]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- CD40 Antigens [D23.050.301.264.051.140]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- CD40 Antigens [D23.101.100.150.140]
Below are MeSH descriptors whose meaning is more specific than "CD40 Antigens".
This graph shows the total number of publications written about "CD40 Antigens" by people in this website by year, and whether "CD40 Antigens" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 1 | 2 |
| 2001 | 1 | 1 | 2 |
| 2004 | 2 | 1 | 3 |
| 2005 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD40 Antigens" by people in Profiles.
-
CD4+ T cell calibration of antigen-presenting cells optimizes antiviral CD8+ T cell immunity. Nat Immunol. 2023 06; 24(6):979-990.
-
The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells. Int J Cancer. 2009 Nov 15; 125(10):2474-8.
-
Using CD40-activated B cells to efficiently identify epitopes of tumor antigens. J Immunother. 2009 Feb-Mar; 32(2):157-60.
-
Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin Cancer Res. 2008 Oct 15; 14(20):6574-9.
-
CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood. 2006 Apr 01; 107(7):2786-9.
-
Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int J Cancer. 2005 Jun 10; 115(2):333-6.
-
DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol. 2004 Dec; 25(12):659-64.
-
Correspondence re R. Lapointe et al., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836-43. Cancer Res. 2004 Jun 01; 64(11):4055-6; author reply 4056-7.
-
CD40 activation: potential for specific immunotherapy in B-CLL. Ann Oncol. 2004 Jun; 15(6):853-7.
-
Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res. 2001 Nov; 7(11):3343-8.
MeSH information
